Agreed Clanger, MPS deal / upfront will be a nice to have, but not a needle mover.
They also threw in a not so subtle hint that Big Pharma were no longer at the top of their lists, but medium / mid tier pharma are their sweet-spot.
I have no idea what changed their target audience (I suspect I know), but good to see they are at least knowledgeable of one and targeting one.
The change in Chinese consultant was interesting as well. I asked the Q why, but no response.
AGM 2024 - QUESTIONS, page-121
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.010(4.55%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 22.8¢ | 23.3¢ | 22.5¢ | $46.92K | 203.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 337 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 138166 | 5 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |